Inactive Instrument

PCAS

PCA

FR0000053514

PCAS Announces Sales Results for September 30, 2020

November 05, 2020 at 12:30 pm EST

PCAS announced sales results for September 30, 2020. For the period, the company reported net sales of €141.3 million representing an decrease of 3.0% compared to the €145.6 million same period in the previous financial year.

Latest news about PCAS

Orapi: takeover bid reopens on February 12	Feb. 09	CF
Orapi: 3.15 million shares tendered to the takeover bid	Feb. 02	CF
Orapi: takeover bid opens on December 27	Dec. 22	CF
PCAS: 200 ME capital increase	Dec. 18	CF
PCAS: OPAS to start this Friday	Nov. 03	CF
PCAS Announces the Consolidated Net Sales Results for the Month of September 30, 2023	23-10-24	CI
Progyny, Inc. : Want to have a baby?	23-10-16
PCAS: Seqens launches minority share offer	23-09-07	CF
PCAS SA Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-05	CI
PCAS SA Reports Consolidated Sales Results for the Period Ended June 30, 2023	23-07-27	CI
DIC Corporation completed the acquisition of PCAS Canada Inc. from PCAS SA.	23-05-31	CI
PCAS: sale of Canadian subsidiary confirmed	23-05-25	CF
PCAS to Divest Canadian Arm to Japan's DIC	23-05-25	MT
DIC Corporation agreed to acquire PCAS Canada Inc. from PCAS SA for an enterprise value of ?88.2 million.	23-05-24	CI
PCAS in Talks to Sell Canada Unit to DIC	23-05-08	CI
PCAS: buoyed by offer for Canadian subsidiary	23-05-03	CF
France's PCAS Enters Exclusive Talks for Canadian Unit Sale to Japan's DIC	23-05-03	MT
PCAS: larger net loss in 2022	23-03-31	CF
Global markets live: Airbus, Manchester United, EA, Credit Suisse, Warner...	23-03-30
PCAS SA Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-29	CI
PCAS SA Reports Consolidated Net Sales Results as of December 31, 2022	23-02-07	CI
PCAS CEO Resigns; Acting Successor Named	22-11-28	MT
Pcas Sa Announces Executive Changes	22-11-28	CI
Pcas Appoints Mr. Jean-Louis Martin as Director	22-11-28	CI
PCAS SA Reports Consolidated Sales Results as of September 30, 2022	22-11-04	CI

Chart PCAS

Duration

Period

More charts

Company Profile

PCAS specializes in developing, manufacturing, and marketing fine and specialty chemicals. Sales are distributed by family of products as follows: - synthesized pharmaceutical products (63.5%); - fine chemicals (36.5%): technical fluids and additives for the lubricant industry, chemical additive synthesis. The group also offers photochemical and new technology products (photosensitive materials, photo-initiators, and polymers for photography, reprography, and micro-electronics). At the end of 2022, the group had 7 production sites located in France (5), Canada and Finland. France accounts for 76% of net sales.

Sector

Pharmaceuticals

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+25.61%	672B
NOVO NORDISK A/S	+25.87%	570B
JOHNSON & JOHNSON	-5.24%	360B
MERCK & CO., INC.	+16.49%	321B
ABBVIE INC.	+8.28%	300B
ASTRAZENECA PLC	+7.09%	217B
ROCHE HOLDING AG	-9.12%	204B
NOVARTIS AG	+5.01%	199B
PFIZER, INC.	-8.75%	149B

Other Pharmaceuticals